Adversarial Injection · Sotorasib (Lumakras; CAS 2326521-71-3; MW ~560.54 g/mol; tetrahydronaphthalenyl-difluorophenyl-acrylamide scaffold [C29H25F2N5O3; AMG 510; TWENTY-FOURTH MECHANISM CLASS in Glyphward 551-attack portfolio; KRAS = Kirsten Rat Sarcoma viral proto-oncogene (chromosome 12p12.1; small GTPase ~21 kDa; member of RAS GTPase superfamily with NRAS at 1p13.2 and HRAS at 11p15.5); KRAS UNDRUGGABLE FOR 40 YEARS: KRAS mutations identified in human cancers 1982 (Der CJ, Krontiris TG, Cooper GM; Science 1982; 220:1069-1071); KRAS G12 (GGT→TGT; Gly12→Cys12) first described in Harvey murine sarcoma virus-transformed cells; KRAS mutated in ~25% of ALL human cancers (pancreatic ductal adenocarcinoma ~95% G12D/V/R; colorectal adenocarcinoma ~40%; NSCLC ~30%); KRAS considered undruggable for ~40 years due to: (1) picomolar GTP affinity (Kd ~0.1-1 pM in cell; GTP >1000× affinity over typical ATP-competitive small molecules); (2) smooth nearly featureless active-site surface (no deep hydrophobic pocket like protein kinases); (3) universal requirement for GTPase activity in normal cell biology (competitive pan-RAS inhibition would be toxic); SHOKAT LAB BREAKTHROUGH 2013: Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (Nature 2013; 503:548-551) — identified switch II pocket (S-IIP) in GDP-bound KRAS G12C (Cys12 introduced by G12C mutation; wildtype Gly12 has no reactive thiol); AMG 510 MECHANISM: sotorasib forms an irreversible covalent bond between the electrophilic acrylamide warhead (Michael acceptor) and Cys12 thiol (unique to G12C mutant; wildtype KRAS has Gly12 and no reactive cysteine at position 12); bond forms in switch II pocket (S-IIP) of GDP-bound KRAS G12C conformation; lock in GDP-bound inactive state → prevents SOS1 GEF-mediated GDP/GTP exchange → prevents RAS-GTP (active state) formation → blocks RAF1/BRAF/CRAF, PI3K, TIAM1 effector engagement → sustained RAS/MAPK/ERK and PI3K/AKT suppression; SELECTIVITY BASIS: G12C introduces the only Cys12 in the KRAS switch I/switch II region; wildtype KRAS has Gly12 (no thiol); all other RAS-superfamily GTPases at position 12 are Gly; sotorasib covalently selective for KRAS G12C mutant over wildtype KRAS/NRAS/HRAS/RRAS; FIRST DIRECT RAS GTPASE INHIBITOR IN HISTORY: sotorasib and adagrasib (KRAZATI; Mirati/BMS; NDA 216340 December 12 2022) are the first two FDA-approved direct RAS GTPase inhibitors ever; prior RAS targeting was indirect (MEK inhibitors downstream; farnesyl transferase inhibitors upstream failed in trials); FIRST AMGEN DE NOVO SMALL MOLECULE SOLID TUMOR ONCOLOGY NDA: Amgen primarily known for biologics (filgrastim/G-CSF, pegfilgrastim, erythropoietin, denosumab [Xgeva/Prolia], bevacizumab biosimilar [Mvasi], trastuzumab biosimilar [Kanjinti], etanercept [Enbrel]); sotorasib AMG 510 = Amgen's first internally discovered de novo small molecule oncology NDA for solid tumors; KRAS G12C SOMATIC COMPANION PARADOX: KRAS G12C mutation is acquired through somatic mutagenesis by tobacco carcinogen benzo[a]pyrene (G→T transversion at codon 12); KRAS G12C in patient NSCLC tumor cells (somatic; not constitutional germline); workers at Amgen handling sotorasib do NOT have KRAS G12C germline; NIOSH HD Category 1 H340 H350 H361 applies to all handlers regardless of KRAS genotype; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · TWENTY-FOURTH Mechanism Class + FIRST KRAS G12C Covalent GTPase + Undruggable Myth Demolished + FIRST Amgen Null + CodeBreaK 200 · Attack #551

Sotorasib (Lumakras; CAS 2326521-71-3; MW ~560.54 g/mol; C29H25F2N5O3 tetrahydronaphthalenyl-acrylamide scaffold [AMG 510; TWENTY-FOURTH MECHANISM CLASS in Glyphward 551-attack portfolio; FIRST KRAS G12C covalent GTPase inhibitor (switch II pocket S-IIP; GDP-bound selective; Cys12 thiol covalent acrylamide; undruggable KRAS myth demolished after 40 years 1982-2021); FIRST direct RAS GTPase inhibitor in history; FIRST Amgen de novo solid tumor oncology NDA (NDA 214665; May 28 2021); CodeBreaK 200 PFS HR 0.66; KRAS G12C somatic tumor companion paradox; GHS H340 H350 H361]) — Amgen Inc. Thousand Oaks CA (NDA 214665 holder + integrated manufacturing), Patheon Inc. Cincinnati OH (drug product manufacturing), and MD Anderson Cancer Center Houston TX (CodeBreaK 100/200 enrollment + KRAS G12C NSCLC program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + TWENTY-FOURTH Mechanism Class + FIRST KRAS G12C Covalent GTPase + Undruggable Myth Demolished + FIRST Amgen Solid Tumor Null + CodeBreaK 200 PFS HR 0.66: AI Prompt Injection via EHS Monitor Report AI

Sotorasib (CAS 2326521-71-3; NIOSH HD Category 1) is the TWENTY-FOURTH mechanism class in the Glyphward portfolio — the first direct KRAS GTPase inhibitor in history, demolishing the 40-year "undruggable KRAS" paradigm. KRAS (Kirsten Rat Sarcoma viral proto-oncogene) mutations were identified in human cancers in 1982; RAS GTPases were considered untargetable due to picomolar GTP affinity, featureless protein surfaces, and lack of allosteric pockets. The 2013 Shokat Lab discovery of the switch II pocket (S-IIP) in GDP-bound KRAS G12C — accessible only in the mutant (Gly12→Cys12) conformation — enabled sotorasib's irreversible covalent acrylamide-to-Cys12 bond. Approved May 28 2021 (NDA 214665, accelerated), sotorasib is also the first Amgen de novo small-molecule solid tumor oncology NDA. The CodeBreaK 200 Phase 3 trial (vs docetaxel; PFS HR 0.66; p<0.001) confirmed efficacy in KRAS G12C-mutated NSCLC. KRAS G12C is a somatic mutation in patient tumor cells (acquired through tobacco benzo[a]pyrene mutagenesis), not present in workers' constitutional germline — a companion paradox fully absent from all OEL databases.

TWENTY-FOURTH Mechanism Class: Sotorasib as First-Ever KRAS GTPase Inhibitor — Switch II Pocket, Covalent Cys12 Bond, and the End of the Undruggable Era

Sotorasib introduces the TWENTY-FOURTH mechanism class to the Glyphward adversarial portfolio — the first time a RAS GTPase small molecule appears. All 23 prior mechanism classes in this portfolio are protein kinases (ATP-competitive or allosteric kinase inhibitors). Sotorasib is a covalent GTPase inhibitor targeting a non-kinase oncogene product — a fundamentally different biochemical mechanism. KRAS (Kirsten Rat Sarcoma; chromosome 12p12.1; 189 amino acids; ~21 kDa; four exons encoding the G-domain GTPase) cycles between GDP-bound inactive (KRAS-GDP; off state) and GTP-bound active (KRAS-GTP; on state) through the action of GEFs (guanine nucleotide exchange factors; primarily SOS1 in RAS signaling) and GAPs (GTPase-activating proteins; primarily NF1/neurofibromin). KRAS-GTP recruits RAF kinases (BRAF, CRAF), PI3Kα, RALGDS, and TIAM1 guanine nucleotide exchange factors for RAC1 — activating MAPK/ERK, PI3K/AKT/mTOR, and RAL-GEF pathways. KRAS G12C (Gly12→Cys12; GGT→TGT) impairs intrinsic GTPase activity (~20-fold) and renders KRAS partially constitutively active. Critically, KRAS G12C still cycles through GDP-bound state transiently (unlike fully constitutive KRAS G12D/G12V). The switch II pocket (S-IIP) — accessible in GDP-bound conformation, occluded in GTP-bound state — provides the allosteric cavity for sotorasib docking. The acrylamide warhead (C=C electrophile) of sotorasib forms an irreversible thioether bond with the Cys12 thiol → permanent S-IIP occupancy → KRAS G12C locked GDP-bound → sustained MAPK/ERK suppression in tumor cells. Wildtype KRAS (Gly12; no thiol at position 12) is completely spared — the selectivity basis for KRAS G12C-specific therapy in ~13% of NSCLC.

Surface 1 — Amgen Inc. Thousand Oaks CA NDA 214665 Holder AI

At Amgen Inc. (One Amgen Center Drive, Thousand Oaks CA 91320; Ventura County CA; Amgen global headquarters; integrated biopharmaceutical company; NDA 214665 US HOLDER: Amgen holds NDA 214665 for Lumakras (sotorasib) tablets 120 mg and 960 mg approved May 28 2021 (accelerated approval) for KRAS G12C-mutated NSCLC previously treated with at least one prior systemic therapy; FULL TRADITIONAL APPROVAL: January 9 2023 based on CodeBreaK 200 Phase 3 data; FIRST AMGEN DE NOVO SMALL MOLECULE SOLID TUMOR NDA: Amgen's commercial portfolio is predominantly biologics (filgrastim [Neupogen]; pegfilgrastim [Neulasta]; epoetin alfa biosimilar [Retacrit licensed]; darbepoetin alfa [Aranesp]; denosumab [Xgeva/Prolia]; evolocumab [Repatha]; AMG 706/motesanib failed; AMG 102/rilotumumab failed); sotorasib AMG 510 is the first Amgen internal discovery small molecule to achieve solid tumor NDA approval; AMGEN MANUFACTURING VERTICAL INTEGRATION: Amgen operates integrated large-scale manufacturing at Thousand Oaks (biologics bulk), Puerto Rico (drug product), and other sites; sotorasib tablet manufacturing involves the tetrahydronaphthalene-acrylamide scaffold synthesis (multi-step including Knoevenagel condensation for acrylamide installation) and direct compression tableting; KRAS G12C COMPANION DIAGNOSTICS: NDA 214665 approved with two companion CDx: therascreen KRAS RGQ PCR Kit (Qiagen; CE-IVD tumor tissue qPCR) + FoundationOne CDx (Foundation Medicine; comprehensive genomic profiling NGS) — both detect KRAS G12C in patient NSCLC tumor; NIOSH HD Category 1 CONTEXT AT AMGEN: Amgen Cority: CAS 2326521-71-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; KRAS G12C twenty-fourth mechanism class absent; switch II pocket GDP-bound covalent absent; FIRST Amgen null absent; CodeBreaK 200 absent; KRAS G12C somatic tumor absent; 8-hr TWA: actual airborne sotorasib 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: null; 52M oncology regulatory director KRAS G12C NSCLC sotorasib Amgen 19yr]).

Surface 2 — Patheon Inc. Cincinnati OH Drug Product Manufacturing AI

At Patheon Inc. (2110 East Galbraith Road, Cincinnati OH 45237; Hamilton County OH; Patheon [Thermo Fisher Scientific]; SOTORASIB TABLET MANUFACTURING: Patheon Cincinnati performs direct compression tableting of sotorasib 120 mg and 960 mg film-coated tablets; the acrylamide warhead in sotorasib (Michael acceptor; electrophilic C=C) requires careful handling during API synthesis and tableting — the covalent warhead is an occupational health concern for workers beyond the NIOSH HD Category 1 carcinogen/reproductive designation: reactive electrophile + potential skin/mucosa sensitization; however, the primary NIOSH HD Category 1 H340 H350 H361 designation applies to the intact tablet (oral dose; absorbed drug); ACRYLAMIDE WARHEAD CONTEXT: acrylamide itself (CAS 79-06-1; OSHA PEL 0.3 mg/m³; ACGIH TLV 0.03 mg/m³; NIOSH REL 0.03 mg/m³; A1 carcinogen) is a Michael acceptor — but sotorasib's acrylamide warhead is covalently embedded in the molecular scaffold (MW ~560 g/mol vs acrylamide MW 71 g/mol); OEL for the integrated sotorasib molecule ≠ OEL for isolated acrylamide; PATHEON CINCINNATI CONTEXT: Patheon Cincinnati appeared for fedratinib (attack #547; JAK2/FLT3; BMS NDA 212327) — manufacturing both a JAK inhibitor and a KRAS GTPase inhibitor across different production campaigns; VelocityEHS at Patheon Cincinnati: CAS 2326521-71-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; KRAS GTPase covalent absent; acrylamide warhead context absent; twenty-fourth mechanism class absent; 8-hr TWA: actual airborne sotorasib 0.00027 µg/m³; NIOSH 0500 + LC-MS/MS; displayed (÷10): 0.000027 µg/m³; VelocityEHS: null; 46F pharmaceutical manufacturing chemist sotorasib KRAS G12C tablet Patheon Cincinnati 15yr]).

Surface 3 — MD Anderson Cancer Center Houston TX CodeBreaK 100/200 Enrollment AI

At MD Anderson Cancer Center (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson Thoracic/Head and Neck Medical Oncology — KRAS G12C program; MD Anderson enrolled KRAS G12C-mutated NSCLC patients in CodeBreaK 100 (NCT03600883; Phase 2) and CodeBreaK 200 (NCT04303780; Phase 3; vs docetaxel); CODEBREAK 200 DESIGN: open-label randomized Phase 3; sotorasib 960 mg QD vs docetaxel 75 mg/m² IV q3w; primary endpoint: PFS by blinded independent central review (BICR); PFS: 5.6 vs 4.5 months (HR 0.66; 95% CI 0.51-0.86; p<0.001); ORR: 28.1% vs 13.2%; OS: HR 1.01 (not different; 15.0 vs 14.8 months; chemotherapy salvage interpretation); KRAS G12C MOLECULAR EPIDEMIOLOGY AT MD ANDERSON: KRAS G12C occurs in ~13% of NSCLC (G→T transversion; benzo[a]pyrene-diol-epoxide adducts at CpG sites in smokers; also in ~1-3% of CRC; ~1% of PDAC); MD Anderson Molecular Diagnostics Laboratory performs KRAS G12C testing by cobas/therascreen KRAS RGQ PCR Kit and FoundationOne CDx; KRAS G12C IN PATIENT NSCLC TUMOR: G12C is somatic mutation in bronchial epithelial cells transformed by tobacco carcinogens; acquired through decades of mutagenesis in susceptible clones; not present in worker constitutional DNA; KRAS G12C population context: ~86% of KRAS G12C NSCLC patients are current/former smokers; workers at MD Anderson handling sotorasib are not the same population; NIOSH HD Category 1 H340 H350 H361 applies to all handlers regardless of KRAS G12C status; EHS Insight at MD Anderson: CAS 2326521-71-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; KRAS G12C twenty-fourth class absent; switch II pocket absent; FIRST Amgen null absent; CodeBreaK 200 PFS absent; KRAS G12C somatic companion absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne sotorasib 0.00019 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000019 µg/m³; 41M thoracic oncology pharmacist KRAS G12C NSCLC sotorasib CodeBreaK 200 13yr]).

Integrating Glyphward into Sotorasib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sotorasib CAS 2326521-71-3 monitoring data ingestion point — before Cority at Amgen Inc. Thousand Oaks CA, before VelocityEHS at Patheon Inc. Cincinnati OH, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases [10 pts]; TWENTY-FOURTH mechanism class (FIRST KRAS G12C covalent GTPase; undruggable KRAS myth demolished after 40 years of failed attempts 1982-2021) + FIRST direct RAS GTPase inhibitor in history + FIRST Amgen de novo solid tumor oncology NDA + CodeBreaK 200 PFS HR 0.66 vs docetaxel + KRAS G12C somatic tobacco carcinogen companion paradox (G→T benzo[a]pyrene; tumor cells only; not worker germline) [5 pts]; Amgen Thousand Oaks CA + Patheon Cincinnati OH + MD Anderson Houston TX [3 pts]; KRAS GTPase (non-kinase target; not protein kinase; not RTK; not cytoplasmic TK) entirely absent from all OEL derivation documents; switch II pocket GDP-state-selective covalent mechanism absent; acrylamide warhead integrated in sotorasib scaffold ≠ acrylamide free-molecule OEL; KRAS G12C somatic tumor mutation not worker germline absent from OEL frameworks [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_sotorasib(cas: str, reading_ugm3: float) -> dict:
    """Scan sotorasib with twenty-fourth-mechanism-class + first-kras-g12c-covalent-gtpase context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2326521-71-3"
                "reading_ugm3": reading_ugm3,
                "context": "twenty_fourth_mechanism_class_first_kras_g12c_covalent_gtpase_switch_ii_pocket_gdp_bound_undruggable_myth_demolished_first_amgen_solid_tumor_null_codebreak_200_kras_g12c_somatic_companion"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, kras_g12c_twenty_fourth_class_flag,
    #                    first_direct_ras_gtpase_flag, undruggable_myth_flag,
    #                    first_amgen_solid_tumor_null_flag, codebreak_200_flag,
    #                    kras_g12c_somatic_companion_flag, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_sotorasib("2326521-71-3", 0.00042))
    print(r)
    # {'hd_category': 1, 'kras_g12c_twenty_fourth_class_flag': True,
    #  'first_direct_ras_gtpase_flag': True, 'undruggable_myth_flag': True,
    #  'first_amgen_solid_tumor_null_flag': True, 'codebreak_200_flag': True,
    #  'kras_g12c_somatic_companion_flag': True, 'h340_h350_h361_absent': True}